LUNG CANCER

Data continue to support the use of RET inhibitors is patients with RET fusion-positive non–small cell lung cancer.

Following the FDA approval of sotorasib for the treatment of KRAS G12C-positive non–small cell lung cancer, there is a great deal of interest in the KRAS inhibitor and its potential benefit.

Small cell lung cancer is the most aggressive form of lung cancer and mostly occurs in smokers. Although the disease has proved to be sensitive to chemotherapy and radiation, responses are short and those who relapse have short survival.

In an interview with Targeted Oncology, Solange Peters, MD, discussed the significance of the 3-year follow-up analysis of the CheckMate 743 study of nivolumab/ipilimumab in mesothelioma.

Data from the phase 3 POSEIDON trial were presented during the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

In a 73-year-old patient, a PET scan revealed activity in the left upper lobe mass, supraclavicular nodal areas, and liver lesions, and an MRI discovered 1 small asymptomatic brain lesion. This lead to a diagnosis of stage T3N3M1-IV extensive-stage small cell lung cancer.

A 59-year-old man with a history of smoking, hypertension, and osteoarthritis presented with chest pain, cough, and dyspnea.

In an interview with Targeted Oncology, Nino Balanchivadze, MD, FACP, discussed the toxicity profile of platinum pemetrexed with pembrolizumab in patients with nonsquamous NSCLC treated in the KEYNOTE-189 study and how demographics and clinical characteristics may impact treatment.

An otherwise healthy 60-year-old White woman presented with a nonproductive cough. She was was later diagnosed with NSCLC.

A 59-year-old White man presented with chest pain, cough, and dyspnea. The patient was diagnosed with poorly differentiated adenocarcinoma of the lung.

In a patient case reviewed by Gilberto De Lima Lopes, MD, a 59-year-old man presented with chest pain, cough, and dyspnea.

A 59-year-old man presented with dyspnea on exertion, fatigue, anorexia, and a 5-lb weight loss. He received the diagnosis of stage IVA adenocarcinoma and had an ECOG performance status of 1.

New NCCN guidelines are available for oncologists on treating and counseling patients with small cell lung cancer.

Solange Peters, MD, PhD, the president of the European Society of Medical Oncology, discusses the use of immunotherapy for the treatment of mesothelioma.

Molecular testing for a patient with lung cancer revealed a RET fusion and PD-L1 expression of 80%.

In this case scenario, a 59-year-old White man presented with chest pain, cough, and dyspnea. The patient was later diagnosis with non–small cell lung cancer.

In an interview prior to the NY Symposium, Perez-Soler, reviewed several areas of development in the lung cancer field that will be addressed during this year’s meeting.

During a Targeted Oncology™ Cased-Based Roundtable event, Meghan Mooradian, MD, discussed the case of a 73-year-old patient with extensive stage-small cell lung cancer.

According to early clinical trial results, taletrectinib can induce responses in patients with ROS1-positive non–small cell lung cancer.

Robert Coleman, MD, FACOG, FACS, discussed how immunotherapy in lung cancer has been widely accepted and adopted in the community oncology setting.

Compared with the median PFS reported in the durvalumab arm of the phase 3 PACIFIC trial in patients with stage III non–small cell lung cancer, the median real-world progression-free survival with durvalumab was higher.

In patients with extensive-stage small cell lung cancer, durvalumab added to platinum/etoposide chemotherapy continued to demonstrate an overall survival improvement compared with chemotherapy alone with a favorable safety profile, according to updated data from the phase 3 CASPIAN trial.

Blood-based tumor mutational burden was hypothesized to be predictive of benefit on atezolizumab treatment in patients with non–small cell lung cancer, but a study has shown otherwise.

Results from the MRTX-500 trial show that sitravatinib administered in combination with nivolumab can elicit durable response and lead to robust survival outcomes for patients with non-small cell lung cancer who progressed after deriving benefit from treatment with a checkpoint inhibitor and/or platinum doublet chemotherapy.

Exploratory results from the phase 3 IMpower010 trial look positive fo the use of adjuvant atezolizumab in various non–small cell lung cancer populations.

In patients with advanced/metastatic non-small cell lung cancer with actionable genomic alterations, datopotamab deruxtecan, an antibody drug conjugate, demonstrated safe antitumor activity.

Can ALK inhibitors have the same impact on other malignancies that harbor ALK rearrangements as is has on non–small cell lung cancer?

Compared indirectly with real-world data of patients treated with standard of care, mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy.

A 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression was seen with brigatinib compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.